Precision genetic cellular models identify therapies protective against endoplasmic reticulum stress
Authors:
- Irina V. LebedevaILIrina V. Lebedeva
- Michelle V. WagnerMWMichelle V. Wagner
- Sunil SahdeoSSSunil Sahdeo
- Yi-Fan LuYLYi-Fan Lu
- Anuli Anyanwu-OfiliAAAnuli Anyanwu-Ofili
- Matthew B. HarmsMHMatthew B. Harms
- Jehangir S. WadiaJWJehangir S. Wadia
- Gunaretnam RajagopalGRGunaretnam Rajagopal
- Michael J. BolandMBMichael J. Boland
- David B. GoldsteinDGDavid B. Goldstein
Preprint
Abstract
Congenital disorders of glycosylation (CDG) and deglycosylation (CDDG) are a collection of rare pediatric disorders with symptoms that range from mild to life threatening. They typically affect multiple organ systems and usually present with neurological abnormalities including hypotonia, cognitive impairment, and intractable seizures. Several genes have been implicated in the thirty-six types of CDG, but currently NGLY1 is the only known CDDG gene. A common biological mechanism among CDG types and in CDDG is endoplasmic reticulum (ER) stress. Here, we develop two isogenic human cellular models of CDG ( PMM2 , the most prevalent type of CDG, and DPAGT1 ) and of the only CDDG ( NGLY1 ) in an effort to identify drugs that can alleviate ER stress. Systematic phenotyping identified elevated ER stress and autophagy levels among other cellular and morphological phenotypes in each of the cellular models. We screened a complex drug library for compounds able to correct aberrant morphological phenotypes in each of the models using an agnostic phenotypic cell painting assay based on >300 cellular features. The image-based screen identified multiple candidate compounds able to correct aberrant morphology, and we show a subset of these are able to correct cellular and molecular defects in each of the models. These results provide new directions for the treatment of rare diseases of glycosylation and deglycosylation and a framework for new drug screening paradigms for more common neurodegenerative diseases characterized by ER stress. Summary sentence: Novel drug screening modality identifies compounds that correct aberrant molecular phenotypes in precision cellular models of glycosylation defects.Keywords
All Related Versions
- Published version: Cell Death & Disease, 12 (8), 1.
This publication has 59 references indexed in Scilit:
- ER stress and the unfolded protein response in neurodegenerationNature Reviews Neurology, 2017
- Endoplasmic Reticulum Malfunction in the Nervous SystemFrontiers in Neuroscience, 2017
- Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum–associated degradation pathwayGenetics in Medicine, 2014
- Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylationMolecular Brain, 2013
- Understanding Human Glycosylation Disorders: Biochemistry Leads the ChargeJournal of Biological Chemistry, 2013
- Endoplasmic reticulum dysfunction in neurological diseaseThe Lancet Neurology, 2013
- Congenital disorders of glycosylationAnnals of the New York Academy of Sciences, 2010
- Deficiency of UDP-GlcNAc:Dolichol Phosphate N-Acetylglucosamine-1 Phosphate Transferase (DPAGT1) Causes a Novel Congenital Disorder of Glycosylation Type IjHuman Mutation, 2003
- Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13 in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome)Nature Genetics, 1997
- Mechanism of action of tunicamycin on the UDP-GlcNAc:dolichyl-phosphate GlcNAc-1-phosphate transferaseBiochemistry, 1979